The EPS beat and regulatory catalysts (ketamine ANDA decision Q3 2026, NRX-101 IND acceptance) are positive, but the company remains pre-revenue from pharmaceutical sales and operating losses are widening. Monitor the Q3 2026 FDA ANDA decision and the Geneuro asset acquisition closing for the next major catalysts. The $7M ATM raise post-quarter provides runway but dilutes existing holders.
Price Chart
Executive Summary
NRx Pharmaceuticals reported Q1 2026 EPS of -$0.04, beating consensus of -$0.13 by 69.2%, with net loss narrowing to $1.4M from $5.5M a year ago. The company advanced multiple regulatory milestones including an anticipated FDA ANDA decision on preservative-free ketamine in Q3 2026, initiated commercial manufacturing, and generated first revenue from its HOPE Therapeutics clinic network. The beat is notable for a clinical-stage biotech but driven by non-recurring fair value accounting changes rather than operational improvement.
Key Financial Metrics
Key Facts
- EPS -$0.04 vs consensus -$0.13 (69.2% beat)
- Net loss narrowed to $1.4M from $5.5M YoY, though operating loss widened to $4.7M from $3.8M
- Cash and equivalents $6.7M as of March 31, 2026; raised ~$7M post-quarter via ATM
- FDA ANDA decision on preservative-free ketamine expected Q3 2026 with favorable preliminary determinations
- Initiated commercial manufacturing at 1 million dose/month scale; FDA reclassified facility to VAI status
- First revenue generated from five HOPE Therapeutics clinics with VA, DoD, and private insurer funding
- Pending acquisition of Geneuro SA assets (patents, antibodies, Phase 2 data) via Swiss court liquidation
- FDA accepted IND for NRX-101 as adjunct to robotic TMS; non-dilutive federal funding anticipated
Financial Impact
EPS beat of 69.2% on a -$0.13 consensus; net loss improvement of $4.1M YoY; $6.7M cash plus $7M post-quarter ATM proceeds
Risk Factors
- FDA ANDA decision on ketamine could be delayed or result in a Complete Response Letter
- Operating losses are widening ($4.7M vs $3.8M) despite net loss improvement from non-recurring items
- Dilution risk from ongoing ATM facility; $7M raised post-quarter adds to share count
- Clinical-stage biotech with no approved products; revenue from clinics is early-stage and small
- Pending Geneuro acquisition may not close or deliver expected value
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3296477 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 16, 2026 16d ago | 8-K | $3.35 $3.16 | ▼ −5.67% | ▼ −8.24% | $2.90 (−13.28%) |
Sep 14, 2026 18d ago | 8-K | $3.49 $3.29 | ▼ −5.73% | ▼ −5.84% | $2.90 (−16.76%) |
Aug 17, 2026 6w ago | 8-K | $3.43 $3.45 | ▲ +0.58% | ▲ +1.77% | $2.90 (−15.31%) |
Aug 17, 2026 6w ago | Press Release | $3.43 $3.45 | ▲ +0.58% | ▲ +1.77% | $2.90 (−15.31%) |
Aug 7, 2026 8w ago | 8-K | $3.58 $3.27 | ▼ −8.66% | ▼ −9.06% | $2.90 (−18.85%) |
Jul 22, 2026 10w ago | 8-K | $4.48 $3.23 | ▼ −27.90% | ▼ −25.50% | $2.90 (−35.16%) |
Jun 22, 2026 14w ago | Press Release | $3.90 $3.73 | ▼ −4.36% | ▼ −2.29% | $2.90 (−25.51%) |
Jun 5, 2026 17w ago | Press Release | $4.14 $3.84 | ▼ −7.25% | ▼ −7.82% | $2.90 (−29.83%) |
Jun 4, 2026 17w ago | Press Release | $4.14 $3.84 | ▲ +7.25% | ▲ +7.82% | $2.90 (+29.83%) |
Jun 3, 2026 17w ago | Press Release | $4.05 $3.76 | ▲ +7.16% | ▲ +3.34% | $2.90 (+28.27%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access